CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home Item
Exercise, the Fountain of Youth? , homeOct. 15, 2026, 5:30 p.m. (Reception at 5 p.m.) | Zhen Yan, Ph.D., Professor and Director, Center for Exercise Medicine Research, Fralin Biomedical Research Institute at VTC | Maury Strauss Distinguished Public Lecture
-
Home Item
Data-Driven Discovery of Secreted Proteins as Cancer Immunotherapies , homeOct. 16, 2026, 11:00 a.m. | Peng Jiang, Ph.D., Senior Investigator, National Cancer Institute, National Institutes of Health | Co-Sponsored by the Fralin Biomedical Research Institute and the Cancer Research Center — D.C.
-
Home Item
Mapping Different Excitatory and Inhibitory Input Types onto Single Cortical Pyramidal Neurons , homeOct. 30, 2026, 11:00 a.m. | Elly Nedivi, Ph.D., William R. (1964) & Linda R. Young Professor of Neuroscience, The Picower Institute for Learning & Memory, Departments of Brain and Cognitive Sciences, and Biology, Massachusetts Institute of Technology | Co-Sponsored by the Fralin Biomedical Research Institute and the Center for Neurobiology Research
-
Home Item
Drug Discovery in the Next Decade: From Genome Medicine to Clinical Trial in a Dish , homeNov. 5, 2026, 5:30 p.m. (Reception at 5 p.m.) | Joseph Wu, M.D., Ph.D., Professor and Director, Stanford Cardiovascular Institute, Stanford University School of Medicine | Maury Strauss Distinguished Public Lecture
-
Home Item
Presenting Therapeutic Peptides Using Synthetic Polymers , homeNov. 13, 2026, 11:00 a.m. | Rachel A. Letteri, Ph.D., Associate Professor, Departments of Chemical Engineering, University of Virginia | Co-Sponsored by the Fralin Biomedical Research Institute and the Center for Vascular and Heart Research
-
Home Item
The Bitter Truth: Alcohol Use and Its Effects on Chemosensory Function , homeDec. 11, 2026, 11:00 a.m. | Paule V. Joseph, Ph.D., MBA, Lasker Clinical Research Scholar, NIH Distinguished Scholar, Acting Chief, Section of Sensory Science and Metabolism Unit, NIDCD; Co-Director, National Smell and Taste Center; Attending Nurse Practitioner, Division of Intramural Clinical and Biological Research; National Institute on Alcohol Abuse and Alcoholism, National Institute on Deafness and Other Communication Disorders | Co-Sponsored by the Fralin Biomedical Research Institute and the Center for Health Behaviors Research